Analyst Reco. Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
12.02 ^USD	+2.82%		-3.14%	+128.52%

29/04	Stoke Therapeutics Appoints Thomas Leggett CFO	MT
29/04	Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on Stoke Therapeutics to $13 From $6, Maintains Neutral Rating	26/03	MT
Needham Adjusts Stoke Therapeutics' Price Target to $22 From $14, Maintains Buy Rating	26/03	MT
Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $21 From $18, Keeps Buy Rating	26/03	MT
Wedbush Adjusts Stoke Therapeutics' Price Target to $17 From $13, Keeps Outperform Rating	26/03	MT
Canaccord Genuity Adjusts Stoke Therapeutics Price Target to $21 From $18, Maintains Buy Rating	26/03	MT
TD Cowen Upgrades Stoke Therapeutics to Outperform From Market Perform	26/03	MT
Wedbush Lowers Stoke Therapeutics' Price Target to $13 From $18, Shifts STK-001 Launch Timing; Retains Outperform Rating	08/23/08	MT
Wedbush Adjusts Stoke Therapeutics Price Target to $18 From $22, Maintains Outperform Rating	25/23/25	MT
Cantor Fitzgerald Adjusts Price Target on Stoke Therapeutics to $25 From $20, Keeps Overweight Rating	23/23/23	MT
Wedbush Lowers Stoke Therapeutics' Price Target to $22 From $25 on Higher Share Count, Keeps Outperform Rating	05/23/05	MT
BofA Securities Upgrades Stoke Therapeutics to Neutral From Underperform, Adjusts Price Target to $12 From $9	01/23/01	MT
Canaccord Genuity Assumes Stoke Therapeutics at Buy With $24 Price Target	26/23/26	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $28 From $32, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating	07/23/07	MT
Wedbush Lowers Stoke Therapeutics' Price Target to $25 From $33, Pushes Out STK-001 Launch Timing By 1 Year; Keeps Outperform Rating	07/23/07	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $32 From $38, Keeps Outperform Rating	11/23/11	MT
HC Wainwright Adjusts Stoke Therapeutics' Price Target to $35 From $70, Keeps Buy Rating	05/22/05	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $38 From $50, Keeps Outperform Rating	15/22/15	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $50 from $54, Maintains Outperform Rating	09/22/09	MT
Cantor Fitzgerald Adjusts Price Target for Stoke Therapeutics to $38 From $68, Retains Overweight Rating	26/22/26	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $54 from $58, Keeps Outperform Rating	11/22/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Analyst Reco.

Filters